EPS for Kura Oncology, Inc. (KURA) Expected At $-0.33; 11 Bullish Analysts Covering Premier, Inc. (PINC)

April 25, 2018 - By Linda Rogers

Premier, Inc. (NASDAQ:PINC) Logo

Analysts expect Kura Oncology, Inc. (NASDAQ:KURA) to report $-0.33 EPS on May, 21.They anticipate $0.06 EPS change or 15.38% from last quarter’s $-0.39 EPS. After having $-0.37 EPS previously, Kura Oncology, Inc.’s analysts see -10.81% EPS growth. The stock decreased 1.99% or $0.3 during the last trading session, reaching $14.8. About 261,182 shares traded. Kura Oncology, Inc. (NASDAQ:KURA) has risen 116.28% since April 25, 2017 and is uptrending. It has outperformed by 104.73% the S&P500.

Among 18 analysts covering Premier (NASDAQ:PINC), 11 have Buy rating, 0 Sell and 7 Hold. Therefore 61% are positive. Premier had 42 analyst reports since August 25, 2015 according to SRatingsIntel. Robert W. Baird maintained Premier, Inc. (NASDAQ:PINC) on Tuesday, August 22 with “Buy” rating. KeyBanc Capital Markets maintained the shares of PINC in report on Tuesday, October 3 with “Buy” rating. The firm has “Buy” rating by Oppenheimer given on Tuesday, August 22. The firm has “Overweight” rating given on Wednesday, June 1 by Barclays Capital. As per Tuesday, August 25, the company rating was maintained by Canaccord Genuity. SunTrust maintained it with “Buy” rating and $40.0 target in Tuesday, October 3 report. As per Wednesday, October 7, the company rating was maintained by Oppenheimer. The stock of Premier, Inc. (NASDAQ:PINC) earned “Underperform” rating by Bank of America on Monday, November 7. The stock has “Buy” rating by Citigroup on Tuesday, August 23. The stock has “Buy” rating by Topeka Capital Markets on Tuesday, August 25. See Premier, Inc. (NASDAQ:PINC) latest ratings:

27/02/2018 Broker: Bank of America Rating: Buy New Target: $39.0
13/02/2018 Broker: Cowen & Co Rating: Market Perform New Target: $35 Initiates Coverage On
08/02/2018 Broker: SunTrust Rating: Buy New Target: $38.0 Maintain
06/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $32.0 Maintain
19/01/2018 Broker: Evercore Rating: In-Line New Target: $33.5 Initiates Coverage On
10/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $37.0 Maintain
19/12/2017 Broker: J.P. Morgan Rating: Hold New Target: $30.0 Downgrade
19/12/2017 Broker: JP Morgan Old Rating: Overweight New Rating: Neutral Downgrade
16/11/2017 Broker: SunTrust Rating: Buy New Target: $36.0 Maintain

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. The company has market cap of $481.90 million. The Company’s pipeline consists of small molecule product candidates that target cancer. It currently has negative earnings. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia.

Among 3 analysts covering Kura Oncology (NASDAQ:KURA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kura Oncology had 4 analyst reports since December 16, 2015 according to SRatingsIntel. The company was initiated on Friday, January 22 by JMP Securities. Oppenheimer initiated Kura Oncology, Inc. (NASDAQ:KURA) on Wednesday, December 30 with “Outperform” rating. As per Wednesday, December 16, the company rating was initiated by Citigroup. Oppenheimer initiated the shares of KURA in report on Thursday, February 11 with “Outperform” rating.

Premier, Inc., together with its subsidiaries, operates as a healthcare improvement firm in the United States. The company has market cap of $4.50 billion. The firm operates through two divisions, Supply Chain Services and Performance Services. It currently has negative earnings. The Supply Chain Services segment offers its members with access to a range of services and products, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and document shredding services and software-as-a-service informatics products.

Since February 8, 2018, it had 0 buys, and 5 insider sales for $1.82 million activity. 3,967 Premier, Inc. (NASDAQ:PINC) shares with value of $125,833 were sold by D’ARCY STEPHEN R.. Another trade for 4,000 shares valued at $137,320 was sold by Price Kelli L.. $215,563 worth of stock was sold by McKasson Craig S. on Monday, March 12. The insider DeVore Susan D. sold $1.30M. 1,177 Premier, Inc. (NASDAQ:PINC) shares with value of $37,487 were sold by Anderson Leigh.

Premier, Inc. (NASDAQ:PINC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>